AlphAIAlphAI — Financial news for AI agents
stocktitan.netSEP 241 min read$CLBT

Cellebrite Shareholders Approve CEO Pay Package

Cellebrite DI Ltd. shareholders approved CEO Shiven Ramji's pay package, re-elected directors, and re-appointed auditors at their annual meeting on September 24, 2026. 80.9% of shares were represented, per the company's SEC filing.

Original reporting
stocktitan.net
Published Sep 24, 2026, 8:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 24, 2026, 9:53 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefCorporate actions
Primary signal
$CLBT
Neutral
high confidence
Mentioned
$CLBT
Relevance
5/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$CLBTNeutralLow
01

Why it matters

The filing confirms governance actions but does not alter the company's financial outlook.

02

Market read

A routine corporate governance update with limited trading relevance.

03

What to watch

Potential future compensation changes tied to performance milestones.

Relevance 5/10Novelty 5/10Timing: post‑meeting Sep 24 2026

Background

Cellebrite DI Ltd. filed a Form 6‑K reporting its annual general meeting outcomes.

Company-level read

Ticker impact

$CLBTNeutralHigh confidence
Context

Shareholders approved the CEO compensation package at the annual meeting.

Expected impact

Minimal price movement expected.

Evidence & confidence

Routine corporate action; market typically reacts little.

Market effects

Sector

None significant for the digital forensics sector.

Regional

Limited to Israeli‑listed companies; no broader regional effect.

Global

Low; only relevant to CLBT shareholders.

Counterpoint

What could challenge this read

If investors view executive pay as excessive, a short‑term dip could occur.

Key entities

  • company
    Cellebrite DI Ltd.

    Digital forensics and data extraction firm listed on Nasdaq (CLBT).

  • executive
    Shiven Ramji

    Chief Executive Officer whose compensation was approved.

Read at source← All news

Related articles

AUG 20
$CLBTMedAI 8/10

Cellebrite (CLBT) Q2 2026 Earnings Call Transcript

Cellebrite (CLBT) announced Shiv Ramji as its new CEO, replacing Tom Hogan. The company missed Q2 revenue expectations due to delayed large transactions and lower-than-expected ARR uplift. Despite this, they raised their full-year adjusted EBITDA target. Ramji outlined plans to improve sales execution and forecasting discipline. The company sees growth in new products and federal business, with a 25% increase in Defense and Intelligence ARR.

yahoo.com3 min
AUG 16
$CLBTMedAI 8/10

Why Cellebrite DI (CLBT) Is Down 30.4% After Cutting 2026 Outlook And Announcing CEO Transition

Cellebrite DI Ltd. reported half-year 2026 results and cut its full-year revenue outlook to US$555 million to US$561 million, implying 17% to 18% growth. The company also announced a CEO transition, with Shiven Ramji succeeding Thomas E. Hogan. The guidance reduction, weaker profitability, and delayed large government contracts contributed to a sharp stock drop.

simplywall.st6 min
AUG 15
$CLBTMedAI 8/10

Cellebrite DI Ltd. Q2 2026 Earnings Call Summary

Cellebrite DI Ltd. reported Q2 2026 results below expectations, citing delayed large transactions and procurement hurdles tied to foreign entity status. Full-year ARR guidance was cut to $550m–$560m, while adjusted EBITDA was raised to $153m–$159m. Management said Insights installed base reached 65% and Genesis launched with $400k ARR.

yahoo.com6 min
AUG 14
$CLBTMed

Cellebrite (CLBT) Stock Rebounds As ARR Grows But Outlook Cools

Simply Wall St reports Cellebrite (CLBT) shares rose about 3% after results despite a prior 30% drop. Q2 revenue was US$131.1m (up from US$113.3m), while ARR was US$508m (up from US$420m). Management raised full-year adjusted EBITDA margin guidance to the high 20s but trimmed ARR outlook to US$550m to US$560m.

simplywall.st3 min